Drug Profile
CHF 6366
Alternative Names: CHF-6366Latest Information Update: 23 Feb 2022
Price :
$50
*
At a glance
- Originator Chiesi Farmaceutici
- Class Antiasthmatics
- Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 23 Feb 2022 Discontinued - Phase-I/II for Asthma in United Kingdom (Inhalation) (Chiesi Farmaceutici pipeline, February 2022)
- 23 Feb 2022 Discontinued - Phase-I/II for Chronic obstructive pulmonary disease in United Kingdom (Inhalation) (Chiesi Farmaceutici pipeline, February 2022)
- 14 May 2021 Safety and pharmacokinetics data from phase I/II trial in Chronic obstructive pulmonary disease presented at 117th International Conference of the American Thoracic Society (ATS-2021)